Literature DB >> 10567375

Regulation of the biosynthesis of N-acetylglucosaminylpyrophosphoryldolichol, feedback and product inhibition.

E L Kean1, Z Wei, V E Anderson, N Zhang, L M Sayre.   

Abstract

The assembly of the core oligosaccharide region of asparagine-linked glycoproteins proceeds by means of the dolichol pathway. The first step of this pathway, the reaction of dolichol phosphate with UDP-GlcNAc to form N-acetylglucosaminylpyrophosphoryldolichol (GlcNAc-P-P-dolichol), is under investigation as a possible site of metabolic regulation. This report describes feedback inhibition of this reaction by the second intermediate of the pathway, N-acetylglucosaminyl-N-acetylglucosaminylpyrophosphoryldolichol (GlcNAc-GlcNAc-P-P-dolichol), and product inhibition by GlcNAc-P-P-dolichol itself. These influences were revealed when the reactions were carried out in the presence of showdomycin, a nucleoside antibiotic, present at concentrations that block the de novo formation of GlcNAc-GlcNAc-P-P-dolichol but not that of GlcNAc-P-P-dolichol. The apparent K(i) values for GlcNAc-P-P-dolichol and GlcNAc-GlcNAc-P-P-dolichol under basal conditions were 4.4 and 2.8 microM, respectively. Inhibition was also observed under conditions where mannosyl-P-dolichol (Man-P-dol) stimulated the biosynthesis of GlcNAc-P-P-dolichol; the apparent K(i) values for GlcNAc-P-P-dolichol and GlcNAc-GlcNAc-P-P-dolichol were 2.2 and 11 microM, respectively. Kinetic analysis of the types of inhibition indicated competitive inhibition by GlcNAc-P-P-dolichol toward the substrate UDP-GlcNAc and non-competitive inhibition toward dolichol phosphate. Inhibition by GlcNAc-GlcNAc-P-P-dolichol was uncompetitive toward UDP-GlcNAc and competitive toward dolichol phosphate. A model is presented for the kinetic mechanism of the synthesis of GlcNAc-P-P-dolichol. GlcNAc-P-P-dolichol also exerts a stimulatory effect on the biosynthesis of Man-P-dol, i.e. a reciprocal relationship to that previously observed between these two intermediates of the dolichol pathway. This network of inhibitory and stimulatory influences may be aspects of metabolic control of the pathway and thus of glycoprotein biosynthesis in general.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567375     DOI: 10.1074/jbc.274.48.34072

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression.

Authors:  Juan A Martínez; José J Tavárez; Caroline M Oliveira; Dipak K Banerjee
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

2.  Biochemical characterization and membrane topology of Alg2 from Saccharomyces cerevisiae as a bifunctional alpha1,3- and 1,6-mannosyltransferase involved in lipid-linked oligosaccharide biosynthesis.

Authors:  Michael Kämpf; Birgit Absmanner; Markus Schwarz; Ludwig Lehle
Journal:  J Biol Chem       Date:  2009-03-12       Impact factor: 5.157

3.  Hetero-oligomeric interactions between early glycosyltransferases of the dolichol cycle.

Authors:  Christine Noffz; Sabine Keppler-Ross; Neta Dean
Journal:  Glycobiology       Date:  2009-01-07       Impact factor: 4.313

4.  Identification and characterization of transcriptional control region of the human beta 1,4-mannosyltransferase gene.

Authors:  Tetsuo Takahashi; Takashi Nedachi; Takuya Etoh; Hiroyuki Tachikawa; Xiao-Dong Gao
Journal:  Cytotechnology       Date:  2015-11-25       Impact factor: 2.058

5.  Translation attenuation by PERK balances ER glycoprotein synthesis with lipid-linked oligosaccharide flux.

Authors:  Jie Shang; Ningguo Gao; Randal J Kaufman; David Ron; Heather P Harding; Mark A Lehrman
Journal:  J Cell Biol       Date:  2007-02-26       Impact factor: 10.539

Review 6.  Genetic defects in dolichol metabolism.

Authors:  Anna Buczkowska; Ewa Swiezewska; Dirk J Lefeber
Journal:  J Inherit Metab Dis       Date:  2014-10-01       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.